Literature DB >> 25564516

Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis.

Capucine Van Rechem1, Joshua C Black1, Myriam Boukhali1, Martin J Aryee2, Susanne Gräslund3, Wilhelm Haas1, Cyril H Benes1, Johnathan R Whetstine4.   

Abstract

UNLABELLED: Chromatin-modifying enzymes are predominantly nuclear; however, these factors are also localized to the cytoplasm, and very little is known about their role in this compartment. In this report, we reveal a non-chromatin-linked role for the lysine-specific demethylase KDM4A. We demonstrate that KDM4A interacts with the translation initiation complex and affects the distribution of translation initiation factors within polysome fractions. Furthermore, KDM4A depletion reduced protein synthesis and enhanced the protein synthesis suppression observed with mTOR inhibitors, which paralleled an increased sensitivity to these drugs. Finally, we demonstrate that JIB-04, a JmjC demethylase inhibitor, suppresses translation initiation and enhances mTOR inhibitor sensitivity. These data highlight an unexpected cytoplasmic role for KDM4A in regulating protein synthesis and suggest novel potential therapeutic applications for this class of enzyme. SIGNIFICANCE: This report documents an unexpected cytoplasmic role for the lysine demethylase KDM4A. We demonstrate that KDM4A interacts with the translation initiation machinery, regulates protein synthesis and, upon coinhibition with mTOR inhibitors, enhances the translation suppression and cell sensitivity to these therapeutics. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25564516      PMCID: PMC4355328          DOI: 10.1158/2159-8290.CD-14-1326

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  23 in total

Review 1.  The TOR pathway: a target for cancer therapy.

Authors:  Mary-Ann Bjornsti; Peter J Houghton
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

Review 2.  Examining the impact of gene variants on histone lysine methylation.

Authors:  Capucine Van Rechem; Johnathan R Whetstine
Journal:  Biochim Biophys Acta       Date:  2014-05-23

3.  Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Authors:  Patrick J Roberts; Jerry E Usary; David B Darr; Patrick M Dillon; Adam D Pfefferle; Martin C Whittle; James S Duncan; Soren M Johnson; Austin J Combest; Jian Jin; William C Zamboni; Gary L Johnson; Charles M Perou; Norman E Sharpless
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

4.  Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofilament organization.

Authors:  Laura T Donlin; Christian Andresen; Steffen Just; Eugene Rudensky; Christopher T Pappas; Martina Kruger; Erica Y Jacobs; Andreas Unger; Anke Zieseniss; Marc-Werner Dobenecker; Tobias Voelkel; Brian T Chait; Carol C Gregorio; Wolfgang Rottbauer; Alexander Tarakhovsky; Wolfgang A Linke
Journal:  Genes Dev       Date:  2012-01-12       Impact factor: 11.361

Review 5.  Targeting mTOR signaling pathway in ovarian cancer.

Authors:  S Mabuchi; T Hisamatsu; T Kimura
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  The comparison of impedance-based method of cell proliferation monitoring with commonly used metabolic-based techniques.

Authors:  Lucie Vistejnova; Jana Dvorakova; Martina Hasova; Tomas Muthny; Vladimir Velebny; Karel Soucek; Lukas Kubala
Journal:  Neuro Endocrinol Lett       Date:  2009       Impact factor: 0.765

Review 7.  Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.

Authors:  Eva Maria Ciruelos Gil
Journal:  Cancer Treat Rev       Date:  2014-03-26       Impact factor: 12.111

8.  KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.

Authors:  Alexandros Tzatsos; Polina Paskaleva; Francesco Ferrari; Vikram Deshpande; Svetlana Stoykova; Gianmarco Contino; Kwok-Kin Wong; Fei Lan; Patrick Trojer; Peter J Park; Nabeel Bardeesy
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

Review 9.  KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.

Authors:  William L Berry; Ralf Janknecht
Journal:  Cancer Res       Date:  2013-05-03       Impact factor: 12.701

10.  SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.

Authors:  Pawel K Mazur; Nicolas Reynoird; Purvesh Khatri; Pascal W T C Jansen; Alex W Wilkinson; Shichong Liu; Olena Barbash; Glenn S Van Aller; Michael Huddleston; Dashyant Dhanak; Peter J Tummino; Ryan G Kruger; Benjamin A Garcia; Atul J Butte; Michiel Vermeulen; Julien Sage; Or Gozani
Journal:  Nature       Date:  2014-05-21       Impact factor: 49.962

View more
  27 in total

1.  Histone demethylases and their roles in cancer epigenetics.

Authors:  Alexandra D'Oto; Qing-Wu Tian; Andrew M Davidoff; Jun Yang
Journal:  J Med Oncol Ther       Date:  2016

2.  Downregulation of histone demethylase JMJD1C inhibits colorectal cancer metastasis through targeting ATF2.

Authors:  Cheng Chen; Maimaiti Aihemaiti; Xin Zhang; Hui Qu; Qi-Long Sun; Qing-Si He; Wen-Bin Yu
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

Review 3.  Lysine Methylation Regulators Moonlighting outside the Epigenome.

Authors:  Evan M Cornett; Laure Ferry; Pierre-Antoine Defossez; Scott B Rothbart
Journal:  Mol Cell       Date:  2019-09-19       Impact factor: 17.970

4.  From histones to ribosomes: a chromatin regulator tangoes with translation.

Authors:  Scott B Rothbart; Bradley M Dickson; Brian D Strahl
Journal:  Cancer Discov       Date:  2015-03       Impact factor: 39.397

5.  Cross-talk between Lysine-Modifying Enzymes Controls Site-Specific DNA Amplifications.

Authors:  Sweta Mishra; Capucine Van Rechem; Sangita Pal; Thomas L Clarke; Damayanti Chakraborty; Sarah D Mahan; Joshua C Black; Sedona E Murphy; Michael S Lawrence; Danette L Daniels; Johnathan R Whetstine
Journal:  Cell       Date:  2018-07-26       Impact factor: 41.582

6.  KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.

Authors:  Ling-Yu Wang; Chiu-Lien Hung; Yun-Ru Chen; Joy C Yang; Junjian Wang; Mel Campbell; Yoshihiro Izumiya; Hong-Wu Chen; Wen-Ching Wang; David K Ann; Hsing-Jien Kung
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423

7.  Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.

Authors:  Tae-Dong Kim; Fang Jin; Sook Shin; Sangphil Oh; Stan A Lightfoot; Joseph P Grande; Aaron J Johnson; Jan M van Deursen; Jonathan D Wren; Ralf Janknecht
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

8.  Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.

Authors:  John R Horton; Amanda Engstrom; Elizabeth L Zoeller; Xu Liu; John R Shanks; Xing Zhang; Margaret A Johns; Paula M Vertino; Haian Fu; Xiaodong Cheng
Journal:  J Biol Chem       Date:  2015-12-08       Impact factor: 5.157

9.  AKT Inhibition Promotes Nonautonomous Cancer Cell Survival.

Authors:  Xavier Solé; Cleidson P Alves; Ipsita Dey-Guha; Laila Ritsma; Myriam Boukhali; Ju H Lee; Joeeta Chowdhury; Kenneth N Ross; Wilhelm Haas; Shobha Vasudevan; Sridhar Ramaswamy
Journal:  Mol Cancer Ther       Date:  2015-12-04       Impact factor: 6.261

Review 10.  Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.

Authors:  Tianshu Yang; Yunkai Yang; Yan Wang
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.